The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction
Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde
Authors
Mihaljević, Olgica![](/themes/MirageInTOR/images/orcid.png)
Živančević-Simonović, Snežana
![](/themes/MirageInTOR/images/orcid.png)
Lučić-Tomić, Aleksandra
Živković, Irena
![](/themes/MirageInTOR/images/orcid.png)
Minić, Rajna
![](/themes/MirageInTOR/images/orcid.png)
Mijatović-Teodorović, Ljiljana
![](/themes/MirageInTOR/images/orcid.png)
Jovanović, Zorica
![](/themes/MirageInTOR/images/orcid.png)
Anđelković, Marija
![](/themes/MirageInTOR/images/orcid.png)
Stanojević-Pirković, Marijana
![](/themes/MirageInTOR/images/orcid.png)
Article (Published version)
Metadata
Show full item recordAbstract
Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerosti...n concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p lt 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps.
Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su t...akođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p lt 0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p lt 0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.
Keywords:
beta-cross-laps / bone metabolism / osteocalcin / sclerostin / thyroid dysfunction / beta-cross-laps / koštani metabolizam / osteokalcin / sklerostin / tireoidna disfunkcijaSource:
Journal of Medical Biochemistry, 2020, 39, 4, 436-443Publisher:
- Društvo medicinskih biohemičara Srbije, Beograd i Versita
Funding / projects:
- Preclinical investigation of bioactive substances (RS-41010)
- Molecular determinants of innate immunity in autoimmunity and tumorogenesis (RS-175069)
- The study was supported by the Faculty of Medical Sciences, University of Kragujevac, Serbia (JP 06-12).
DOI: 10.5937/jomb0-24943
ISSN: 1452-8258
WoS: 000575084800004
Scopus: 2-s2.0-85099123003
Collections
Institution/Community
TorlakTY - JOUR AU - Mihaljević, Olgica AU - Živančević-Simonović, Snežana AU - Lučić-Tomić, Aleksandra AU - Živković, Irena AU - Minić, Rajna AU - Mijatović-Teodorović, Ljiljana AU - Jovanović, Zorica AU - Anđelković, Marija AU - Stanojević-Pirković, Marijana PY - 2020 UR - http://intor.torlakinstitut.com/handle/123456789/558 AB - Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p lt 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps. AB - Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p lt 0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p lt 0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom. PB - Društvo medicinskih biohemičara Srbije, Beograd i Versita T2 - Journal of Medical Biochemistry T1 - The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction T1 - Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde EP - 443 IS - 4 SP - 436 VL - 39 DO - 10.5937/jomb0-24943 ER -
@article{ author = "Mihaljević, Olgica and Živančević-Simonović, Snežana and Lučić-Tomić, Aleksandra and Živković, Irena and Minić, Rajna and Mijatović-Teodorović, Ljiljana and Jovanović, Zorica and Anđelković, Marija and Stanojević-Pirković, Marijana", year = "2020", abstract = "Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta-cross-laps). Methods: The study included 30 patients with thyroid dysfunction (hypothyroidism, hyperthyroidism and subclinical hyperthyroidism) and ten euthyroid controls. Free thyroxine (FT4) was measured by radioimmunoassay, while thyroid stimulating hormone (TSH) concentration was determined immunoradiometrically. We used an ELISA kit to determine the sclerostin level. The electrochemiluminescence method was applied for measuring the bone markers. Results: Sclerostin levels were significantly lower in hypothyroid patients (p=0.009) and significantly elevated in hyperthyroid patients (p=0.008) compared to control values. Hyperthyroid patients also had higher sclerostin than patients with subclinical hyperthyroidism (p=0.013). Sclerostin concentrations were negatively correlated with TSH levels (r=-0.746, p lt 0.001), but positively with FT4 (r=0.696, p lt 0.001). Moreover, sclerostin was positively associated with osteocalcin (r=0.605, p=0.005) and beta-cross-laps levels (r=0.573, p=0.008) in all thyroid patients. Conclusions: Serum sclerostin is significantly affected in subjects with thyroid dysfunction. Both sclerostin and thyroid status affect bone homeostasis, which is reflected through the significant correlations with osteocalcin and beta-cross-laps., Uvod: Cilj ove studije bio je da uporedimo serumske koncentracije sklerostina kod pacijenata sa disfunkcijom štitaste žlezde u odnosu na eutiroidne kontrolne ispitanike, i da procenimo odnos između sklerostina i markera koštanog metabolizma (osteokalcina i beta-cross-lapsa) u istoj populaciji. Metode: Studijom je obuhvaćeno 30 pacijenata sa disfunkcijom štitaste žlezde (hipotireozom, hipertireozom i supkliničkom hipertireozom) i 10 eutiroidnih kontrola. Slobodni tiroksin (FT4) meren je radioimunološkom metodom, dok je koncentracija tireostimulišućeg hormona (TSH) određivana imunoradiometrijski. Za merenje nivoa sklerostina koristili smo ELISA-test. Metoda elektrohemiluminiscencije primenjena je za merenje koncentracije koštanih markera. Rezultati: Nivo sklerostina bio je značajno niži kod bolesnika sa hipotireozom (p = 0,009) odnosno značajno viši kod bolesnika sa hipertireozom (p = 0,008) u poređenju sa vrednostima kod eutiroidnih kontrolnih ispitanika. Pacijenti sa hipertireozom su takođe imali statistički značajno viši nivo sklerostina u odnosu na bolesnike sa supkliničkom hipertireozom (p = 0,013). Pokazana je negativna korelacija koncentracije sklerostina i TSH (r = -0,746, p lt 0,001), odnosno pozitivna korelacija sa FT4 (r = 0,696, p lt 0,001) kod pacijenata sa tireoidnom disfunkcijom. Štaviše, sklerostin pozitivno korelira sa koncentracijom osteokalcina (r = 0,605, p = 0,005) i beta-cross-lapsa (r = 0,573, p = 0,008) kod ovih pacijenata. Zaključak: Serumski nivoi sklerostina izmenjeni su kod osoba sa disfunkcijom štitaste žlezde. Sklerostin zajedno sa tireoidnim statusom utiče na koštani metabolizam, što se ogleda u njegovoj značajnoj korelaciji sa osteokalcinom i beta-cross-lapsom.", publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita", journal = "Journal of Medical Biochemistry", title = "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction, Veza cirkulišućeg nivoa sklerostina sa markerima metabolizma kostiju kod pacijenata sa poremećajem rada štitaste žlezde", pages = "443-436", number = "4", volume = "39", doi = "10.5937/jomb0-24943" }
Mihaljević, O., Živančević-Simonović, S., Lučić-Tomić, A., Živković, I., Minić, R., Mijatović-Teodorović, L., Jovanović, Z., Anđelković, M.,& Stanojević-Pirković, M.. (2020). The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry Društvo medicinskih biohemičara Srbije, Beograd i Versita., 39(4), 436-443. https://doi.org/10.5937/jomb0-24943
Mihaljević O, Živančević-Simonović S, Lučić-Tomić A, Živković I, Minić R, Mijatović-Teodorović L, Jovanović Z, Anđelković M, Stanojević-Pirković M. The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction. in Journal of Medical Biochemistry. 2020;39(4):436-443. doi:10.5937/jomb0-24943 .
Mihaljević, Olgica, Živančević-Simonović, Snežana, Lučić-Tomić, Aleksandra, Živković, Irena, Minić, Rajna, Mijatović-Teodorović, Ljiljana, Jovanović, Zorica, Anđelković, Marija, Stanojević-Pirković, Marijana, "The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction" in Journal of Medical Biochemistry, 39, no. 4 (2020):436-443, https://doi.org/10.5937/jomb0-24943 . .